64 / 76
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 3, May/June 2018
194
AFRICA
2013;
168
(3): 486–495.
49. Merola JF, Wu S, Han J, Choi HK, Qureshi AA. Psoriasis, psoriatic arthri-
tis and risk of gout in US men and women.
Ann Rheum Dis
2015;
74
(8):
1495–1500.
50. Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are
at a higher risk of developing nonalcoholic fatty liver disease.
Clin Exp
Dermatol
2015;
40
(7): 722–727.
51. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM.
Patients with severe psoriasis are at increased risk of cardiovascular mortal-
ity: cohort study using the General Practice Research Database.
Eur Heart
J
2010;
31
(8): 1000–1006.
52. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM.
Cause-specific mortality in patients with severe psoriasis: a population-
based cohort study in the U.K.
Br J Dermatol
2010;
163
(3): 586–592.
53. Paoletti R, Gotto AM, Jr, Hajjar DP. Inflammation in atherosclerosis and
implications for therapy.
Circulation
2004;
109
(23 Suppl 1): III20–26.
54. Ray A, Huisman MV, Tamsma JT, Research, Writing g, van Asten J,
et
al
. The role of inflammation on atherosclerosis, intermediate and clinical
cardiovascular endpoints in type 2 diabetes mellitus.
Eur J Intern Med
2009;
20
(3): 253–260.
55. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L,
Simantov R,
et al
. Prevalence and correlates of accelerated atherosclerosis
in systemic lupus erythematosus.
N Engl J Med
2003;
349
(25): 2399–2406.
56. Ridker PM. Clinical application of C-reactive protein for cardiovascular
disease detection and prevention.
Circulation
2003;
107
(3): 363–369.
57. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN,
et al
.
Psoriasis and systemic inflammatory diseases: potential mechanistic links
between skin disease and co-morbid conditions.
J Invest Dermatol
2010;
130
(7): 1785–1796.
58. Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of
systemic inflammation in psoriasis: a systematic review and meta-analysis.
Br J Dermatol
2013;
169
(2): 266–282.
59. Ahima RS, Flier JS. Adipose tissue as an endocrine organ.
Trends
Endocrinol Metab
2000;
11
(8): 327–332.
60. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D’Agostino RB, Sr,
Wilson PW,
et al
. Associations of adiponectin, resistin, and tumor necrosis
factor-alpha with insulin resistance.
J Clin Endocrinol Metab
2008;
93
(8):
3165–3172.
61. Lonnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen
SF. Association of psoriasis with the risk for type 2 diabetes mellitus and
obesity.
J Am Med Assoc Dermatol
2016;
152
(7): 761–767.
62. Egeberg A, Bruun LE, Mallbris L, Gislason GH, Skov L, Wu JJ,
et al
.
Family history predicts major adverse cardiovascular events (MACE) in
young adults with psoriasis.
J Am Acad Dermatol
2016;
75
(2): 340–346.
63. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S,
et al.
Cardiovascular risk factors in patients with plaque psoriasis: a systematic
review of epidemiological studies.
J Eur Acad Dermatol Venereol
2010;
24
(Suppl 2): 23–30.
64. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and
smoking: a systematic review and meta-analysis.
Br J Dermatol
2014;
170
(2): 304–314.
65. Carretero G, Ribera M, Belinchon I, Carrascosa JM, Puig L, Ferrandiz C,
et al.
Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the
Spanish Academy of Dermatology and Venereology.
Actas Dermosifiliogr
2013;
104
(7): 598–616.
66. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxy-
genase: a systematic review of the observational studies of selective and
nonselective inhibitors of cyclooxygenase 2.
J Am Med Assoc
2006;
296
(13): 1633–1644.
67. American Academy of Dermatology Work G, Menter A, Korman NJ,
Elmets CA, Feldman SR, Gelfand JM,
et al
. Guidelines of care for the
management of psoriasis and psoriatic arthritis: section 6. Guidelines
of care for the treatment of psoriasis and psoriatic arthritis: case-based
presentations and evidence-based conclusions.
J Am Acad Dermatol
2011;
65
(1): 137–174.
68. Johnsson H, McInnes IB, Sattar N. Cardiovascular and metabolic risks in
psoriasis and psoriatic arthritis: pragmatic clinical management based on
available evidence.
Ann Rheum Dis
2012;
71
(4): 480–483.
69. Boehncke WH, Boehncke S, Schon MP. Managing comorbid disease in
patients with psoriasis.
Br Med J
2010;
340
: b5666.
70. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman
NJ,
et al
. National Psoriasis Foundation clinical consensus on psoriasis
comorbidities and recommendations for screening.
J Am Acad Dermatol
2008;
58
(6): 1031–1042.
71. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM.
Prevalence of cardiovascular risk factors in patients with psoriasis.
J Am
Acad Dermatol
2006;
55
(5): 829–835.
72. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili
AR,
et al
. Cigarette smoking, body mass index, and stressful life events as
risk factors for psoriasis: results from an Italian case-control study.
J Invest
Dermatol
2005;
125
(1): 61–67.
73. Naldi L, Conti A, Cazzaniga S, Patrizi A, Pazzaglia M, Lanzoni A,
et al.
Diet and physical exercise in psoriasis: a randomized controlled trial.
Br J
Dermatol
2014;
170
(3): 634–642.
74. de Menezes Ettinger JE, Azaro E, de Souza CA, dos Santos Filho PV,
Mello CA, Neves M, Jr,
et al
. Remission of psoriasis after open gastric
bypass.
Obes Surg
2006;
16
(1): 94–97.
75. Hossler EW, Maroon MS, Mowad CM. Gastric bypass surgery improves
psoriasis. J
Am Acad Dermatol
2011;
65
(1): 198–200.
76. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and
mortality in patients with rheumatoid arthritis: a prospective study.
Lancet
2002;
359
(9313): 1173–1177.
77. Cronstein B. How does methotrexate suppress inflammation?
Clin Exp
Rheumatol
2010;
28
(5 Suppl 61): S21–23.
78. Reiss AB, Carsons SE, Anwar K, Rao S, Edelman SD, Zhang H,
et al
.
Atheroprotective effects of methotrexate on reverse cholesterol trans-
port proteins and foam cell transformation in human THP-1 monocyte/
macrophages.
Arthritis Rheum
2008;
58
(12): 3675–3683.
79. Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, Iversen
L,
et al
. Cardiovascular disease event rates in patients with severe psoriasis
treated with systemic anti-inflammatory drugs: a Danish real-world cohort
study.
J Intern Med
2013;
273
(2): 197–204.
80. Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ. Effects
of biologic agents and other disease-modifying antirheumatic drugs on
cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic
review.
Curr Pharm Des
2014;
20
(4): 500–512.
81. Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S.
Thiazolidinediones for plaque psoriasis: a systematic review and meta-
analysis.
Evid Based Med
2012;
17
(6): 171–176.
82. Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B,
et al
.
Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesi-
ty and type 2 diabetes: a prospective cohort study.
J Eur Acad Dermatol
Venereol
2013;
27
(11): 1440–1443.
83. Drucker DJ, Rosen CF. Glucagon-like peptide-1 (GLP-1) receptor agonists,
obesity and psoriasis: diabetes meets dermatology.
Diabetologia
2011;
54
(11): 2741–2744.